Summary: In a small IVUS study in borderline coronary lesions, combining alirocumab with atorvastatin drove LDL-C to 1.48 mmol/L and produced greater plaque regression and lumen gain over 48 weeks than either agent alone, supporting a lower-is-better approach in documented coronary disease.
PICO Summary
| Element | Detail |
|---|---|
| Population | 69 patients with IVUS-detected borderline coronary lesions (60 completed 48 weeks). |
| Intervention | Alirocumab plus atorvastatin (Group C). |
| Comparison | Alirocumab plus placebo (A) or atorvastatin plus placebo (B). |
| Outcome | Combination lowered LDL-C most (3.64→1.48 mmol/L, ~57 mg/dL; p<0.001), with greater lumen-volume increase (p=0.038) and greater plaque-volume reduction (p=0.041) than either monotherapy. No major adverse effects. |
Statin + PCSK9i vs monotherapy on coronary plaque (IVUS)
RCT · borderline coronary lesions · 48 weeks
Adding a PCSK9 inhibitor to atorvastatin drove LDL-C lowest and produced the greatest plaque regression and lumen gain on IVUS over 48 weeks. Small and surrogate-based, so it reinforces rather than redefines a lower-is-better approach.
Expert Commentary
This sits comfortably alongside GLAGOV and the lower-is-better story, and I read it as a positive, mechanistically satisfying result: the arm that reached the lowest LDL-C, around 57 mg/dL, showed the most plaque regression and even lumen gain, consistent with intensive lipid lowering reversing rather than merely stabilising disease. The IVUS endpoint is a genuine strength because it sees plaque within the wall that angiography misses. My discipline here is about weight. With sixty completers across three arms this is small and hypothesis-supporting, the endpoint is a surrogate, plaque volume, not myocardial infarction or revascularisation, and forty-eight weeks is short for atherosclerosis. The placebo-monotherapy comparators are also somewhat artificial, since in practice a patient with coronary disease would receive a statin regardless. Can I use this with my patients? Yes, as reinforcement rather than novelty. For a patient with documented coronary atherosclerosis not at LDL-C goal on a maximally tolerated statin, it strengthens the case for adding a PCSK9 inhibitor and aiming low, and the tangible idea of shrinking plaque can aid adherence. Outcome trials, not this, remain the basis for the decision.
References
Xu Z, Fang Y, Peng Y, Zhang C, Zheng C. Clinical efficacy of atorvastatin and PCSK9 inhibitors in patients with borderline coronary lesions: an intravascular ultrasound assessment. J Cardiovasc Pharmacol Ther. 2025;30:10742484251361059. doi:10.1177/10742484251361059